Propanc Biopharma demonstrates the significant effects of proenzyme therapy on the tumor microenvironment
Scientific director concludes observations applicable to all solid tumors
MELBOURNE, Australia, December 21, 2021– (BUSINESS WIRE) – Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients with recurrent and metastatic cancer, has announced today that Ms. Belen Toledo MSc., from the laboratory of Professor Macarena Perán Ph.D., University of Jaén, Spain, has recently completed an important experimental thesis on the effects of proenzyme therapy and the impact on the tumor microenvironment, which is key to the development, invasion, metastatic spread and recurrence of solid tumors. Ms Toledo also reconfirmed that proenzymes kill cancer stem cells (SCCs). This research is part of the joint research and drug discovery program “Proenzymes Optimization Project 1” (POP1) of the universities of Jaén and Granada, Spain, designed to produce synthetic recombinant quantities on a commercial scale of the two proenzymes, trypsinogen and chymotrypsinogen.
The encouraging results demonstrate that the proenzymes have a specific effect on tumor cells and CSCs, but also affect other tumor elements in the tumor microenvironment. However, Ms. Toledo’s most significant finding is that the proenzymes also caused a reversal of the malignant tumor phenotype, which was “most unexpected, very exciting and powerfully conclusive.” The process that causes a reversal of the tumor phenotype is called differentiation, which is basically how proenzymes exert anti-tumor, anti-cancer, and anti-metastatic effects. Therefore, proenzyme treatment, also known as differentiation therapy, exerts these effects on malignant cells, but leaves healthy cells alone.
“The tumor microenvironment has some characteristics common to all solid tumors. Proenzymes normalize this tumor microenvironment,” said Dr Julian Kenyon Mb., ChB., MD, Scientific Director of Propanc. “Therefore, the process of cell differentiation induced by the proenzymes will be applicable to all cancers from solid tumors, as well as to sarcomas. This is truly a remarkable discovery and may be the key to unlocking the uncontrolled spread of malignant tumors. , the leading cause of death in cancer patients. Based on these results, I believe there is an urgent need to advance our lead product candidate, PRP, into clinical trials. “
The POP1 program is designed to produce a clinical rescue compound for the Company’s primary product candidate, PRP. The goal is to produce large quantities of commercial trypsinogen and chymotrypsinogen that have minimal batch variation and without sourcing proenzymes from animals. Propanc is undertaking this ambitious research project in collaboration with the universities of Jaén and Granada, led by researchers M. Aitor González MSc. and Mrs. Toledo, supported by Profs. Perán and Juan Antonio Marchal, MD, representing the universities respectively, and Dr Kenyon.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors using pancreatic proenzymes that target and eradicate cancer stem cells in patients with cancers of the pancreas, ovary and colorectal. For more information, please visit www.propanc.com.
The company’s new proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes may be the body’s main defense against cancer.
To view the Company’s “Mechanism of Action” video on its anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
All statements other than statements of historical fact contained in this press release are “forward-looking statements”, which can often, but not always, be identified by the use of words such as “could”, “could”, ” will be “,” will probably result “,” should “,” should “,” estimate “,” plan “,” project “,” foresee “,” intend “,” expect “,” anticipate “,” believe ”,“ seek ”,“ continue ”,“ target ”or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern in the absence of new debt or equity financings; the Company’s current reliance on significant debt financing which it is unable to repay in cash; the Company’s ability to successfully remedy material weaknesses in its internal controls; the Company’s ability to meet research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to initiate and successfully complete clinical trials and its ability to successfully develop PRP, its flagship product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and financial expertise; the Company’s dependence on third parties for the services; the Company’s dependence on key managers; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports which are filed with the Securities and Exchange Commission and available on its website at http: // www .sec.gov. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligation to update these statements, except as required by law.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211221005242/en/
Investor and media relations:
Mr. James Nathanielsz
Propanc Biopharma, Inc.